Phenylpropanolamine withdrawal for decongestive uses challenged

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1283, 2001-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulatory Decisions in a Globalised World: The Domino Effect of Phenylpropanolamine Withdrawal in Latin America

By Figueras A. Laporte J.

Drug Safety, Vol. 25, Iss. 10, 2002-01 ,pp. : 689-693

Adis International

Access to resources Recommend Favorite

Phenylpropanolamine-containing products will remain on the market in Spain

Inpharma, Vol. 1, Iss. 1271, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Tiotropium's cost effectiveness challenged in Europe

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 664, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The primacy of β-blockers for hypertension is challenged

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Galicia's new law on generics challenged

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 622, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite